Woodcock Encourages Patient Groups To Take Lead To Speed Regulatory Process, Development
This article was originally published in The Pink Sheet Daily
Executive Summary
Medical and patient communities can help make up for FDA’s resource gaps by developing PRO standards and benefit-risk frameworks for specific diseases, FDA drug chief says.
You may also be interested in...
20 Is The Loneliest Number: FDA Disease Meeting Schedule Leaves Some Worried About Exclusion
Conflict among groups with conditions both included and not included in the preliminary list of public meeting topics prompts FDA to reiterate that the diseases will be selected because better clinical measures are needed, not because the agency will prioritize them over others.
PhRMA’s Vision For 21st Century Marketing Would Reshape Supplemental NDAs
Five-point plan that calls for FDA to change definition of ‘labeling’ and ‘substantial evidence’ may offer hints as to what the next iteration of 21st Century Cures legislation will offer.
Disparity In Breast Cancer Population Is Challenge For FDA: Can Genetic Testing Help?
Breast cancer meeting highlights challenges of patient-focused drug development as breast cancer patients ask for trials to better identify characteristics of super-responders so patients can make more informed risk-benefit decisions.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: